An observational study in Telangiectasia, Hereditary Hemorrhagic, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Telangiectasia, Hereditary Hemorrhagic by Imperial College London — 2 open to participants now, 3 under way, none of them phase 3. Telangiectasia, Hereditary Hemorrhagic · Imperial College London.
Among the 13 studies in Telangiectasia, Hereditary Hemorrhagic by Imperial College London, this one is the only one that started in 2000, is one of 8 observational ones, and was the 1st registered.
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
Browse Telangiectasia, Hereditary Hemorrhagic studies →2 of the 13 studies in Telangiectasia, Hereditary Hemorrhagic by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
By country, each count listing its studies:
Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2000.
This study's planned enrollment of 2,000 is above the median of 207 across 41 observational studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Median enrollment 50 across the 5 interventional studies, 128 across the 8 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Telangiectasia, Hereditary Hemorrhagic by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational study is for individuals with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that are reviewed at the Hammersmith Hospital, London.
The Hammersmith Hospital provides a clinical service for patients with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that is unique in the United Kingdom. Measurements obtained as part of standard clinical practice that has evolved since 1985 allow us to assess whether particular groups of individuals that we see are more prone to recognised complications such as strokes, brain abscesses, pregnancy related complications or pulmonary hypertension. We hypothesise that certain clinical characteristics will predict the susceptibility of individuals to particular complications.
Patients referred to the hereditary haemorrhagic telangiectasia clinical service at Hammersmith Hospital, imperial College Healthcare NHS Trust
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Stroke
Ischaemic stroke attributable to PAVMs
Time frame: Prospective
Venous thromboemboli (VTE)
VTE of any origin
Time frame: Prospective
Started Jan 2000 (actual). Primary completion is estimated for Jan 2028, 336 months after the start.
Of 23 observational studies under Telangiectasia, Hereditary Hemorrhagic, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 184. This study's planned 336 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Telangiectasia, Hereditary Hemorrhagic →